A DEA judge cancelled a hearing to consider a proposal to reclassify marijuana amid allegations that officials at the agency ...

DEA Administrative Law Judge John Mulrooney has canceled the first hearings on the proposal to reschedule cannabis to a Schedule III drug after ...

AdvisorShares Pure US Cannabis, a popular exchange-traded fund tracking marijuana stocks, slid 3.6% to $3.44 on Thursday, hovering near an all-time low hit the day before. Shares of the biggest ...

Biden's proposal to ease restrictions on marijuana was delayed due to allegations of misconduct against the DEA.

The Drug Enforcement Administration (DEA) is asking an agency judge to reject a request to have it removed from upcoming ...

A Drug Enforcement Administration (DEA) judge is condemning the agency over its “unprecedented and astonishing” defiance of a ...

The cannabis industry faces significant challenges. While the proposed rescheduling of cannabis could provide some tax and ...

DEA's refusal to comply with direct orders is “unprecedented and astonishing," says the judge overseeing the marijuana ...

In 2025, cannabis faces major changes with federal reclassification, easing regulations, increasing research, and opening ...

DEA judge orders agency to respond to allegations of opposing marijuana rescheduling and improper communication with opponents. Cannabis stocks declined in 2024 due to concerns about DEA review.

Advocates accuse Drug Enforcement Administration of blocking the reclassification of cannabis as a Schedule III drug under ...

Company views delay as imperative administrative step and symbolic win for industry against conflicted DEA –– Company condemns agency ...